This morning BioNTech dropped a bombshell. Co-founders Prof. Ugur Sahin and Prof.
Özlem Türeci, the two scientists who built the mRNA platform that produced the world's first approved COVID-19 vaccine, announced they are leaving the company by end of 2026 to start a new independent mRNA-focused biotech.
BioNTech will contribute related mRNA technology rights to the new venture in exchange for a minority stake and potential milestones and royalties. The stock immediately sold off 14%, wiping approximately $4.26 billion from the company's market cap in a single session.
The market treated this like an existential event. It is not.
Here is what did not leave with the founders:
15 ongoing Phase 3 oncology trials with multiple late-stage readouts expected in 2026.
A completed acquisition of CureVac in December 2025, expanding BioNTech's mRNA manufacturing and IP portfolio significantly. Positive Phase 2 data from pumitamig in triple-negative breast cancer. A new HIV antibody trial adding depth to the long-term infectious disease pipeline.
A new first-in-human BNT3214 cancer trial initiated this week. A new mpox mRNA vaccine trial launched in Africa. Morgan Stanley maintaining its Buy rating. HC Wainwright maintaining a $140 price target. JP Morgan maintaining $120. UBS at $117. Analyst median target sitting at $131. A strong cash position that management highlighted at the JP Morgan conference in January.
A stated goal of becoming a commercial multi-product oncology company by 2030. The binding agreement for the founders' new venture is not even signed yet, it is expected by end of H1 2026, and the transition does not complete until end of 2026.
The company has time to install new leadership and the pipeline is already in motion.
Now add the Iran war layer. Every modern conflict accelerates biodefense spending.
The US military and allied governments have dramatically increased investment in rapid-response vaccine and therapeutic platforms since COVID-19. BioNTech's mRNA technology is the most validated rapid-response platform on the planet, capable of producing a new vaccine candidate in weeks.
In a conflict environment where biological threats, chemical exposure, and mass casualty scenarios demand fast medical countermeasures, BioNTech's platform is not a liability.
It is infrastructure. Biodefense investment is rising globally and mRNA sits at the center of every serious government preparedness program.
The weekly chart puts this in full context. After a multi-year downtrend from the COVID highs above $400, BioNTech built a long base through 2023 and 2024, broke out hard into late 2025, hit $124 on the 52-week high, and has now retraced sharply back into the prior breakout zone.
Today's founder news accelerated that pullback into two clean weekly demand zones that sit directly on long-term Fibonacci support levels. The red SMA 200 is still declining as overhead resistance but the green SMA 20 is trying to curl at a historically significant horizontal level.
🟢 Buy Zone 1 ($65.92 area)
Price has been driven into the 0.618 Fibonacci retracement of the entire 2024 to 2025 breakout move. The weekly candle is printing a long lower wick as institutional buyers absorb the panic selling. This is the first high-probability demand zone with a defined stop below the prior consolidation base.
Stop: $2.50 below entry (3.792%) / $45,000 position
Qty: 2,000
Risk/Reward Ratio: 11.94
Target: +45.297% ($95.78 area / $109,720)
🟢 Buy Zone 2 ($51.17 area)
If broader market risk-off and continued founder transition uncertainty pushes BNTX toward the 0.786 Fibonacci level and the lower boundary of the multi-year base, this is the entry with maximum R/R before a full trend reversal would be confirmed.
Stop: $2.50 below entry (4.886%) / $45,000 position
Qty: 2,000
Risk/Reward Ratio: 11.94
Target: +58.355% ($81.17 area / $109,720)
Key Levels:
🔑 Current Price: $83.40
🔑 Buy Zone 1: ~$65.92 area
🔑 Buy Zone 2: ~$51.17 area
🔑 52-Week Low: $76.53
🔑 52-Week High: $124.00
🔑 HC Wainwright Target: $140.00
🔑 Morgan Stanley Target: $131.00
🔑 JP Morgan Target: $120.00
🔑 Analyst Median Target: $131.00
🔑 Phase 3 Trials: 15
🎯 Target: $113 (+45% from Zone 1 / $109,720)
⚠️ Hard Stop Both Zones: $2.50 below entry
The founders built the platform. The platform is what has value now. Fifteen Phase 3 oncology trials do not stop running because the people who started the company are moving on.
The CureVac acquisition does not unwind. The mRNA IP does not disappear. The biodefense contracts do not evaporate. What changed today is sentiment, and sentiment at panic lows on a weekly demand zone is where the setups are made.
The founders left. The pipeline didn't. That is the trade.
If you found this analysis valuable, hit the Follow button at the top of the page. Every idea in this Iran war series, oil, defense, reconstruction, crypto, chips, cyber, AI infrastructure, domestic manufacturing, flash storage, AI data centers, and now biodefense mRNA, is being updated in real time as the conflict develops. You don't want to miss what's coming next.
Özlem Türeci, the two scientists who built the mRNA platform that produced the world's first approved COVID-19 vaccine, announced they are leaving the company by end of 2026 to start a new independent mRNA-focused biotech.
BioNTech will contribute related mRNA technology rights to the new venture in exchange for a minority stake and potential milestones and royalties. The stock immediately sold off 14%, wiping approximately $4.26 billion from the company's market cap in a single session.
The market treated this like an existential event. It is not.
Here is what did not leave with the founders:
15 ongoing Phase 3 oncology trials with multiple late-stage readouts expected in 2026.
A completed acquisition of CureVac in December 2025, expanding BioNTech's mRNA manufacturing and IP portfolio significantly. Positive Phase 2 data from pumitamig in triple-negative breast cancer. A new HIV antibody trial adding depth to the long-term infectious disease pipeline.
A new first-in-human BNT3214 cancer trial initiated this week. A new mpox mRNA vaccine trial launched in Africa. Morgan Stanley maintaining its Buy rating. HC Wainwright maintaining a $140 price target. JP Morgan maintaining $120. UBS at $117. Analyst median target sitting at $131. A strong cash position that management highlighted at the JP Morgan conference in January.
A stated goal of becoming a commercial multi-product oncology company by 2030. The binding agreement for the founders' new venture is not even signed yet, it is expected by end of H1 2026, and the transition does not complete until end of 2026.
The company has time to install new leadership and the pipeline is already in motion.
Now add the Iran war layer. Every modern conflict accelerates biodefense spending.
The US military and allied governments have dramatically increased investment in rapid-response vaccine and therapeutic platforms since COVID-19. BioNTech's mRNA technology is the most validated rapid-response platform on the planet, capable of producing a new vaccine candidate in weeks.
In a conflict environment where biological threats, chemical exposure, and mass casualty scenarios demand fast medical countermeasures, BioNTech's platform is not a liability.
It is infrastructure. Biodefense investment is rising globally and mRNA sits at the center of every serious government preparedness program.
The weekly chart puts this in full context. After a multi-year downtrend from the COVID highs above $400, BioNTech built a long base through 2023 and 2024, broke out hard into late 2025, hit $124 on the 52-week high, and has now retraced sharply back into the prior breakout zone.
Today's founder news accelerated that pullback into two clean weekly demand zones that sit directly on long-term Fibonacci support levels. The red SMA 200 is still declining as overhead resistance but the green SMA 20 is trying to curl at a historically significant horizontal level.
🟢 Buy Zone 1 ($65.92 area)
Price has been driven into the 0.618 Fibonacci retracement of the entire 2024 to 2025 breakout move. The weekly candle is printing a long lower wick as institutional buyers absorb the panic selling. This is the first high-probability demand zone with a defined stop below the prior consolidation base.
Stop: $2.50 below entry (3.792%) / $45,000 position
Qty: 2,000
Risk/Reward Ratio: 11.94
Target: +45.297% ($95.78 area / $109,720)
🟢 Buy Zone 2 ($51.17 area)
If broader market risk-off and continued founder transition uncertainty pushes BNTX toward the 0.786 Fibonacci level and the lower boundary of the multi-year base, this is the entry with maximum R/R before a full trend reversal would be confirmed.
Stop: $2.50 below entry (4.886%) / $45,000 position
Qty: 2,000
Risk/Reward Ratio: 11.94
Target: +58.355% ($81.17 area / $109,720)
Key Levels:
🔑 Current Price: $83.40
🔑 Buy Zone 1: ~$65.92 area
🔑 Buy Zone 2: ~$51.17 area
🔑 52-Week Low: $76.53
🔑 52-Week High: $124.00
🔑 HC Wainwright Target: $140.00
🔑 Morgan Stanley Target: $131.00
🔑 JP Morgan Target: $120.00
🔑 Analyst Median Target: $131.00
🔑 Phase 3 Trials: 15
🎯 Target: $113 (+45% from Zone 1 / $109,720)
⚠️ Hard Stop Both Zones: $2.50 below entry
The founders built the platform. The platform is what has value now. Fifteen Phase 3 oncology trials do not stop running because the people who started the company are moving on.
The CureVac acquisition does not unwind. The mRNA IP does not disappear. The biodefense contracts do not evaporate. What changed today is sentiment, and sentiment at panic lows on a weekly demand zone is where the setups are made.
The founders left. The pipeline didn't. That is the trade.
If you found this analysis valuable, hit the Follow button at the top of the page. Every idea in this Iran war series, oil, defense, reconstruction, crypto, chips, cyber, AI infrastructure, domestic manufacturing, flash storage, AI data centers, and now biodefense mRNA, is being updated in real time as the conflict develops. You don't want to miss what's coming next.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.